

University of Groningen

New expression system from rhodococcus

van der Geize, Robert; Hessels, Gerda; Dijkhuizen, Lubbert; van der Meijden, Peter

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2004

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van der Geize, R., Hessels, G., Dijkhuizen, L., & van der Meijden, P. (2004). New expression system from rhodococcus. (Patent No. WO2004055189).

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/055189 A1

- (51) International Patent Classification⁷: C12N 15/76, 15/11, 1/21, C12Q 1/68
- (21) International Application Number: PCT/EP2003/050928
- (22) International Filing Date: 2 December 2003 (02.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02080054.6 3 December 2002 (03.12.2002) EP
- (71) Applicant (for all designated States except US): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **VAN DER GEIZE, Robert** [NL/NL]; Overijssellaan 14, NL-9642 HS Veenendam (NL). **HESSELS, Gerda** [NL/NL]; Kraaienest 131, NL-9733 HK Groningen (NL). **DIJKHUIZEN, Lubbert** [NL/NL]; Ter Borch 28, NL-9474 RB Zuidlaren (NL). **VAN DER MEIJDEN, Peter** [NL/NL]; Diosynth B.V., NL-5340 BH Oss (NL).
- (74) Agent: **HOGENBIRK, M.**; P.O. Box 20, NL-5340 Oss (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW EXPRESSION SYSTEM FROM *RHODOCOCCUS*



(57) Abstract: Title: The present invention provides an isolated polynucleotide comprising the *kstD* promoter from *Rhodococcus erythropolis*. The polynucleotide can very advantageously be used as a controllable transcription activator. Said controlling function can be provided by providing said isolated polynucleotide with a nucleotide sequence encoding a transcription regulator of said promoter. In the present invention, such a transcription regulator may be externally induced, such as by introduction of steroidal compounds. In an alternative embodiment of the present invention the isolated polynucleotide may comprise the *kstR* gene or a homologue or a functional part thereof as the transcription regulator of the *kstD* promoter.

New expression system from *Rhodococcus*

FIELD OF THE INVENTION

The invention concerns a promoter from *Rhodococcus*, more specifically *Rhodococcus erythropolis*, its regulation and the use of this promoter and its regulation as an expression system in heterologous applications.

BACKGROUND OF THE INVENTION

Actinomycetes, and especially bacteria of the genus *Rhodococcus* are renowned for their ability to metabolise complex molecules. Several species of *Rhodococcus* are able to degrade fuel, benzene, and even TNT and they are therefore widely studied in the field of microbiology which concerns the biochemical pathways and cell factories. Among the micro-organisms which oxidize natural and anthropogenic hydrocarbons and which are active participants in biogeochemical processes of the biosphere, e.g. contributing to producing a hydrocarbon-free atmosphere for the Earth, the genus *Rhodococcus* takes a predominant place.

Several *Rhodococcus* species also degrade natural phytosterols, which proceeds via the formation of steroids as pathway intermediates. These steroids may in turn be used as precursors in the production of pharmaceutically active compounds.

In order to produce pharmaceutical precursor compounds as pathway intermediates of microbes in high amounts, production strains are routinely transformed to optimise the expression of the genes of interest and/or block certain metabolic routes in order to achieve accumulation of the intermediates. Such transformation often involves the heterologous expression of proteins. With the increased use of *Rhodococcus* and other Actinomycetic bacteria (such as *Mycobacterium*, *Arthrobacter*, *Nocardia*, *Corynebacterium* and *Brevibacterium* species) for expression of heterologous proteins, there is a

growing need for improved regulation of such expression and for molecular tools.

Presently, mutant strains with desired properties are isolated by classical mutagenesis, such as UV irradiation, but these strains are often inadequate in industrial processes due to genetic instability and/or low bioconversion efficiencies. Molecularly defined (constructed) mutants would present important advantages over mutants generated by classical mutagenesis. Constructed mutants are genetically more stable and the introduced mutations represent well-defined genetic modifications.

Construction of genetically engineered strains by transformation may also make the use of chemical agents to block certain pathways obsolete. Chemical agents used to block enzyme activity mostly are often not reaction specific and may inhibit other important enzymatic reactions, which may have negative effects on bioconversion efficiency. The use of defined mutants by genetic engineering would overcome such problems.

An important enzyme in steroid metabolism, which can, for instance, be found in *Rhodococcus erythropolis*, is 3-ketosteroid Δ^1 -dehydrogenase (KSTD1, EC 1.3.99.4) the gene of which resides in the so-called *kstD1* locus (van der Geize, R. *et al.* 2000. Appl. Environm. Microbiol. 66: 2029-2036).

Although it is known that molecular organization of steroid catabolic genes may differ between different *Rhodococcus* species, homologues of this gene have been found in several other bacteria, such as *Arthrobacter simplex*, *Pseudomonas* spp., *Nocardia restrictus*, *Nocardia corallina*, *Nocardia opaca* and *Mycobacterium fortuitum*. The sequence of the *kstD* gene of *Rhodococcus erythropolis* strain SQ1 has been disclosed by Van der Geize *et al.* in WO 01/31050 and is depicted in SEQ ID NO:1.

From the same bacterial strain an isoenzyme KSTD2 with its corresponding gene *kstD2*, is known. Disruption of the *kstD1* gene has shown not to abolish 3-ketosteroid Δ^1 -dehydrogenase (KSTD) activity completely and

activity remains due to the presence of the isoenzyme (Van der Geize *et al.*, 2002. Microbiology 148:3285-3292; WO 01/31050).

KSTD activity is essential for steroid nucleus degradation and *kstD* gene inactivation is needed to accumulate steroid intermediates. Inactivation
5 of genes is a powerful tool for analysing gene function and for introducing metabolic blocks. Gene disruption with a non-replicative vector carrying a selectable marker is the commonly used method for gene inactivation.

It was found that wild-type KSTD activity in gene disruption mutant *R. erythropolis* SDH420 can be induced by the application of 3-keto- Δ^4 -
10 steroids, such as 4-androstene-3,17-dione, indicating the presence of a steroid-dependent regulatory mechanism. Upstream of the *kstD* gene locus, a gene (ORF2) was identified whose function was hitherto unknown, but was described as a putative regulatory gene carrying the consensus sequence of repressor proteins of the TetR family (Van der Geize, R. *et al.* 2000. Appl.
15 Environ. Microbiol. 66:2029-2036).

It has now been found that a promoter for the *kstD1* gene resides in the *kstD* locus of *Rhodococcus erythropolis* and that this promoter is regulated through repression with the gene product of ORF2 of the bacterium, denominated *kstR* hereafter. It has now also been found that this repression of
20 the *kstD* promoter by the *kstR* gene-product can be overcome by the induction of expression with steroidal compounds. This property of the combination of the *kstD* gene- *kstR* repressor system makes it particularly fit for expression of heterologous proteins in bacteria such as those of the family of Actinomycetes.

25 SUMMARY OF THE INVENTION

In one aspect, the invention relates to an isolated polynucleotide comprising a promoter from *Rhodococcus erythropolis*, characterised in that said promoter is the *kstD* promoter.

The polynucleotide can very advantageously be used as a controllable
30 transcription activator. Said controlling function can be provided by providing

said isolated polynucleotide with a nucleotide sequence encoding a transcription regulator of said promoter. In the present invention, such a transcription regulator may be externally induced, such as by introduction of steroidal compounds.

5 In an alternative embodiment of the present invention the isolated polynucleotide may comprise the *kstR* gene or a homologue or a functional part thereof as the transcription regulator of the *kstD* promoter.

 Since the isolated polynucleotide of the invention can very advantageously be used as a heterologous expression system, the
10 polynucleotide of the invention may further comprise a nucleotide sequence encoding a polypeptide that is operably linked to said promoter.

 In order to provide for selectable traits in the bacteria into which the expression system is transferred, the polynucleotide may further comprise such sequences that encode selectable markers, counter-selectable markers
15 and/or reporter genes.

 In another aspect, the invention relates to a recombinant vector comprising an isolated polynucleotide of the invention. Such a recombinant vector suitably comprises nucleotide sequences that represent multiple cloning sites.

20 The present invention also relates to a method for constructing a genetically modified strain of a micro-organism which micro-organism lacks the ability to degrade the steroid nucleus, the method comprising producing a polynucleotide according to the present invention and transforming the said strain with said polynucleotide.

25 In another aspect the invention relates to a host cell transformed with the recombinant vector of the invention. Said host cell is preferably a bacterium from the order of Actinomycetales. Very suitable host cells are bacteria belonging to the families of *Actinomycetaceae*, *Corynebacterineae*, *Mycobacteriaceae*, *Nocardiaceae*, *Brevibacteriaceae*, or *Micrococcaceae* and in
30 particular those of the genus *Rhodococcus*.

In another aspect, the invention relates to a method for producing a desired protein in a host cell, comprising transforming a host cell with a recombinant vector of the invention.

5 In another aspect, the invention relates to a microbial expression system comprising a polynucleotide of the invention.

In yet another aspect, the invention relates to a method for constitutive expression of a protein of interest comprising transforming a host cell with a polynucleotide construct wherein the expression of the coding region of said protein is under control of the *kstD* promoter.

10 In another aspect, the invention relates to a use of a steroid for the induction of expression of a heterologous protein, which expression is under control of the *kstD* promoter, said steroid lifting the repressor function exerted by the *kstR* gene product.

15

DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of the construction of mutagenic plasmid pREG104 for *kstR* unmarked gene deletion.

20 Figure 2 is a schematic representation of the *Rhodococcus* expression vector pRESX derived from pRESQ (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018). Closed solid curved bar indicates the *kstD* promoter region. Open solid curved bar indicates *Rhodococcus* genes encoding autonomous replication. *aphII* encodes kanamycine resistance.

25 DETAILED DESCRIPTION OF THE INVENTION

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes double- and single-stranded DNA and RNA.

30 The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by

virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature; or (2) is linked to a polynucleotide other than that to which it is linked in nature; or (3) does not occur in nature.

5 "Transformation" and "transforming", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be
10 integrated into the host cell genome.

 By "host cell" is meant a cell which contains a vector and supports the replication and/or expression of the vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are bacterial cells of the order of
15 Actinomycetales.

 As used herein, the term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to another control sequence and/or to a coding sequence is ligated in such a way
20 that transcription and/or expression of the coding sequence is achieved under conditions compatible with the control sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

25 As used herein "promoter" is a DNA sequence that directs the transcription of a (structural) gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a (structural) gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of

transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.

The term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as the modifications known in the art, both naturally occurring and non-naturally occurring.

As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is by deliberate human intervention at a different native genomic locus than in the native state. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, the promoter and the gene are not operably linked in nature. A heterologous protein may originate from a foreign species or, if from the same species, is produced through expression from a heterologous nucleic acid.

A "repressor protein" or "repressor" is a protein that is able to recognize and bind to a nucleotide sequence that is contained in a DNA sequence (operator) that is located 5'-ward of a structural gene. The binding of a repressor protein with its cognate operator results in the inhibition of the transcription of the structural gene.

An "enhancer" is a DNA regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

The term "isolated" refers to material, such as a nucleic acid, which is substantially or essentially free from components that normally accompany

or interact with it as found in its naturally occurring environment. An isolated DNA molecule is a fragment of DNA that has been separated and that is no longer integrated in the genomic DNA of the organism from which it is derived.

5 The term "expression" refers to the biosynthesis of a gene product.

 An "expression vector" is a DNA molecule comprising a gene that is expressed in a host cell. Typically, gene expression is placed under the control of certain regulatory elements, including constitutive or inducible promoters, regulatory elements and/or enhancers. Such a gene is said to be "operably
10 linked to" the regulatory elements and its expression is said to be "under control of" the regulatory elements.

 The term "selectable marker" refers to a polynucleotide sequence encoding a metabolic trait which allows for the separation of transgenic and non-transgenic organisms and mostly refers to the provision of antibiotic
15 resistance. A selectable marker is for example the *aphII* encoded kanamycin resistance marker.

 The term "counter-selectable marker" refers to a polynucleotide sequence whose expression is lethal, instead of giving rise to resistance as is often the case for selectable markers. A counter-selectable marker is for
20 example the *sacB* gene encoding *B. subtilis* levansucrase the expression of which is lethal in the presence of sucrose.

 As used herein, the term "reporter gene" means a gene that encodes a gene product that can be identified. Reporter genes include, but are not limited to, chloramphenicol acetyl transferase, [beta]-galactosidase, luciferase
25 and green fluorescence protein. Identification methods for the products of reporter genes include, but are not limited to, enzymatic assays and fluorimetric assays. Reporter genes and assays to detect their products are well known in the art and are described, for example in Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-
30 Interscience: New York (1987) and periodic updates.

The sequence denoted as ORF2 of *Rhodococcus*, which is depicted in SEQ ID NO:4, has been deemed to be part of the chromosomal gene cluster also harbouring the *kstD1* gene (Van der Geize, R. *et al.* 2000. Appl. Environ. Microbiol. 66:2029-2036), where it is said to encode a TetR type of repressor protein (denominated *kstR*). However, the circumstances under which the repressor function is exercised or lifted have never been disclosed up till now. Also, the relation between the repressor function of *kstR* and the promoter of the *kstD1* gene has hitherto not been established.

In *Arthrobacter simplex* a similar genomic composition of the *kstD* gene and a putative repressor coding ORF (denominated *kdsR*) has been described (Molnar, I. *et al.* 1995. Mol. Microbiol. 15:895-905). In this case, no relation between repressor protein and expression of the steroid enzyme has been established.

The promoter region of the *kstD1* gene has not been exactly determined. The region between the start codons of the *kstD1* gene and the start of the *kstR* gene (which lies in the reverse order compared to the *kstD1* gene) is a sequence of about 158 basepairs, which contains the promoter for the *kstD1* gene and presumably also the promoter for *kstR*. In case this promoter would be working bidirectionally, the expression of gene encoding the repressor protein can also be driven by the *kstD1* promoter.

The promoter according to the invention is the promoter driving expression of the *kstD* gene in *Rhodococcus* and it preferably comprises the nucleotide sequence of 158 base pairs according to SEQ ID NO: 3 or a shortened version thereof (e.g. deleted at the 5' end) which still possesses the functional capacity of a promoter, *i.e.* to drive the expression of a protein which expression it controls. How to arrive at promoter deletion mutants is well known in the art and also the experimentation needed to identify promoter activity for such a deletion mutant comprises no undue burden and is well known to a person skilled in the art. Techniques for polynucleotide manipulation useful for the practice of the present invention are described in a

variety of references, such as Molecular Cloning: A Laboratory Manual, 2nd Ed., Vol. 1-3, eds. Sambrook et al. Cold Spring Harbor Laboratory Press (1989) or Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates
5 thereof.

One skilled in the art would know methods for identifying active fragments of *kstD* promoter, which methods could include, for example, the measurement of transcription of mRNA or the expression of a polypeptide from a reporter gene which requires the addition of a functional promoter. To
10 determine the presence of active *kstD* promoter fragments that are capable of controlling transcription and/or expression of the coding sequence to which it is operably linked, the person skilled in the art will readily understand that a promoter functionality test can be performed therewith. Such a test may for instance comprise the operable linking of a promoter of the invention and a
15 reporter gene in a vector, bringing the vector in a suitable host, exposing the host to conditions suitable for expression and determining the presence of the reporter gene product in order to determine promoter functionality.

While the nucleotide sequence of the promoter (including promoter elements) is given in SEQ ID NO:3, it is recognized that nucleotide
20 substitutions can be made which do not affect the promoter or promoter element function.

One skilled in the art would recognize that point mutations and deletions can be made to the *kstD* promoter sequences disclosed herein without altering the ability of the sequence to activate transcription. In addition, active
25 fragments of the *kstD* promoter can be obtained. Similar methods can be used for identifying other active fragments of the *kstD* promoter. Other methods for identifying an active fragment of the *kstD* promoter are routine and well known in the art. For example, overlapping fragments of the *kstD* promoter can be synthesized and cloned into a suitable expression vector to determine
30 active *kstD* promoter fragments. Similarly, point mutations can be introduced

into the disclosed *kstD* promoter sequences using, for example, site-directed mutagenesis or by synthesizing sequences having random nucleotides at one or more predetermined positions.

The invention includes as an embodiment an isolated polynucleotide
5 comprising a *kstD* promoter or active fragment thereof. These isolated polynucleotides contain less than about 50%, preferably less than about 70%, and more preferably less than about 90% of the chromosomal genetic material with which the *kstD* promoter is usually associated in nature. An isolated polynucleotide "consisting essentially of" a *kstD* promoter lacks other
10 promoters derived from the chromosome on which *kstD* is located. This terminology of "isolated" and "consisting essentially of" is analogously applicable to the *kstR* repressor element. For example, an isolated polynucleotide consisting essentially of a *kstR* repressor lacks polynucleotide material such as enhancers or promoters, respectively, located on the
15 chromosome on which *kstR* is located.

Isolated polynucleotides comprised of or consisting essentially of a *kstD* promoter, and coding for a *kstR* repressor or active fragments thereof, may be prepared by techniques known in the art (e.g., Sambrook, et al.). These techniques include, for example, using the sequence information provided
20 herein to provide primers and probes to amplify by PCR specific regions of *kstD* genomic clones, or by chemical synthesis, or by recombinant means.

A recombinant polynucleotide comprised of a *kstD* promoter or active fragment thereof, as well as those which may be comprised of other *kstD* transcription regulatory elements described herein, may be prepared by any
25 technique to those of skill in the art using the sequence information provided herein.

In the experimental section the promoter is shown to be regulated by the repressor protein, which is presumed to bind to the promoter and thus to inhibit the expression of the protein which it controls. A recombinant
30 polynucleotide comprised of a *kstD* promoter may also be comprised of a coding

sequence for the *kstR* repressor (such as depicted in SEQ ID NO:4) causing repression of *kstD*-promoted gene transcription and providing a regulation mechanism that can be lifted by exposing the cells to an inducer such as described below.

5 A recombinant polynucleotide comprising a *kstD* promoter may also comprise a coding sequence to which the promoter is operably linked, causing transcription of the coding sequence under the control of the promoter. Coding sequences may encode either homologous or heterologous polypeptides. However, they may also encode other moieties which are desirable in their
10 transcribed form. For example, coding sequences may encode, *inter alia*, decoy polynucleotides that bind to transcription factors, anti-sense RNAs, and a variety of polypeptides that are of interest (e.g. viral proteins to serve as intracellular vaccines, proteins that serve as markers, etc.), polypeptides for commercial purposes that are to be expressed in cells that express *kstD*
15 proteins, and particularly proteins that are of use in regulation of cell metabolism and production of pharmaceutical precursors.

For extracellular expression of proteins under control of the promoter a signal sequence can be inserted between the promoter and the DNA coding for the gene of interest. Such a signal sequence is provided to
20 allow targeting of proteins to specific cellular compartments. Preferably this signal sequence is the signal sequence of the gene coding for cholesterol oxidase as present in *R. equi* and as deposited at Genbank under accession number AJ242746 (see also Navas, J. *et al.* 2001. J. Bacteriol. 183:4796-4805).

The promoter can be used in any host cell, but preferably in a
25 prokaryote host cell, more preferably a bacterium from the order of *Actinomycetales*, such as those bacteria belonging to families such as *Actinomycetaceae*, *Corynebacterineae*, *Mycobacteriaceae*, *Nocardiaceae*, *Brevibacteriaceae*, *Micrococcaceae* and the like. More preferably it will be a bacterium of the genus *Rhodococcus*, *Mycobacterium*, *Arthrobacter*, *Nocardia*,
30 *Corynebacterium* or *Brevibacterium*. Most preferably it is a bacterium of the

genus *Rhodococcus* such as a bacterial strain of the species *Rhodococcus aetherovorans*, *Rhodococcus coprophilus*, *Rhodococcus equi*, *Rhodococcus erythreus*, *Rhodococcus erythropolis*, *Rhodococcus fascians*, *Rhodococcus globerulus*, *Rhodococcus jostii*, *Rhodococcus koreensis*, *Rhodococcus*
5 *maanshanensis*, *Rhodococcus marinonascens*, *Rhodococcus opacus*,
Rhodococcus percolatus, *Rhodococcus pyridinivorans*, *Rhodococcus rhodnii*,
Rhodococcus rhodochrous, *Rhodococcus rubber*, *Rhodococcus tukisamuensis*,
Rhodococcus wratislaviensis, *Rhodococcus zopfii* and the like.

Also part of the invention is a bacterial host cell which is equipped
10 with the promoter, without having the gene for the repressor protein.
Preferably this host cell is the bacterium *Rhodococcus erythropolis* RG10 as
deposited under number DSM 15231 with the DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen at October 9, 2002. In this bacterium, as is
15 shown in Example 1, the gene coding for the suppressor protein has been
deleted.

Such a host cell, in which the suppressor gene has been deleted can
be used for the expression of proteins. Preferably (although it may be that the
host cell still has its endogenous *kstD* promoter) a vector harbouring the *kstD*
promoter of the invention which controls the expression of a protein of interest
20 should be introduced in the cell. Constructing such a vector and
transformation or transfection of such a vector into the host cell is common
practice for those skilled in the art. In this way, as is shown in Example 1, the
kstD promoter will be unrepressed and act as a constitutive promoter.

A host cell according to the invention comprising the isolated *kstD*
25 promoter or an active fragment thereof is understood to include the progeny of
the original cell which has been transformed. It is understood that the progeny
of a single parental cell may not necessarily be completely identical in
morphology or in genomic or total DNA complement as the original parent, due
to natural, accidental, or deliberate mutation.

It is recognized that specific nucleotides or regions within the *kstD* promoter elements other than *kstR* may be identified as necessary for regulation. These regions of nucleotides may be located by fine structural dissection of the elements by analyzing the functional capacity of a large
5 number of promoter mutants. Single base pair mutations can be generated utilizing polymerase chain reaction (PCR) technology. U.S. Pat. No. 4,683,202. Mutated promoter regions can be cloned back into reporter constructs using standard techniques and evaluated by transfection into appropriate cells and assayed for reporter gene function. This analysis will also identify nucleotide
10 changes which do not affect promoter function.

A further aspect of the invention is to use the repressor and its inducibility for controlled expression by providing a cell with a sequence that codes for the repressor protein and a sequence coding for a protein that needs to be controllably expressed, where that sequence is operably linked to the
15 *kstD* promoter. The sequence for the *kstR* repressor protein may be encompassed on the same expression construct as the *kstD* promoter-gene of interest construct, but it may also be on a different construct. It is also envisaged that the host cell already contains the repressor gene, either located on a plasmid or on the chromosome. Then, the expression system is established
20 by transforming such a host cell with a construct harbouring the *kstD* promoter. Similarly, the host cell may already contain the promoter controlling the expression of a gene of interest. Addition of the gene coding for the repressor protein then would stop expression of the gene of interest when the repressor protein is produced and expression can be induced again by lifting
25 the repressor function. Also, the expression of the *kstR* repressor sequence may be under the control of a constitutive promoter.

A further method for controlling expression of a gene of interest by the *kstD* - *kstR* system is by replacing the *kstD* gene which is normally under control of the *kstD* promoter by inserting the coding sequence of a gene of
30 interest *in situ* behind the *kstD* promoter. This can be accomplished by

techniques which are commonly known within the art, such as homologous recombination and/or use of recombinases and their recognition sites such as the cre-lox system.

The repression of the *kstD* promoter exerted by the *kstR* gene product can be lifted by addition of a steroid compound, with 3-keto- Δ^4 -functionality. In particular such compounds as 4-androstene-3,17-dione (AD), 1,4-androstadiene-3,17-dione (ADD), estr-4-ene-3,17-dione, testosterone, progesterone, nordione, 7 α -methyl-nordione, 11-methylene-nordione, but also such compounds as pregnenolone and stanolone (17 β -OH-5 α -androstane-3-on), 19-OH-7-dehydro-androstene-3,17-dione and 9 α -hydroxy-4-androstene-3,17-dione (9OHAD) are able to lift *kstD* promoter repression.

Alternative regulatory compounds may also be identified. For instance, cells expressing products of reporter genes under the control of a *kstD* promoter are useful for identifying agents that regulate the activity of a *kstD* promoter. Thus, host cells expressing a reporter gene product under the control of a *kstD* promoter are useful for screening and it is a further object of the invention to provide a method for identifying compounds that regulate the activity of a *kstD* promoter. The method includes exposing a cell containing a *kstD* promoter to at least one compound whose ability to modulate the activity of a *kstD* promoter is sought to be determined. The cells are then monitored for changes caused by the modulation.

EXAMPLES

Example 1. Constitutive expression of *kstD* following *kstR* unmarked gene deletion

Mutagenic plasmid pREG104 was constructed for unmarked gene deletion of *kstR*, the gene encoding a transcription regulator of the *kstD* gene (encoding 3-ketosteroid Δ^1 -dehydrogenase KSTD1) in *Rhodococcus erythropolis* SQ1 (Fig. 1). Briefly, pSDH205 (Van der Geize, R. *et al.* 2000. Appl. Environ. Microbiol. 66:2029-2036) was digested with restriction enzymes *NruI* and *BalI*

followed by self-ligation, resulting in plasmid pREG103. An *EcoRI* DNA fragment of pREG103, containing the *kstR* gene deletion was subsequently cloned into *EcoRI* digested pK18mobsacB vector, resulting in pREG104. Unmarked *kstR* gene deletion mutant *R. erythropolis* RG10 was isolated from

5 *R. erythropolis* SQ1 using pREG104 via the *sacB* counter-selection method as described (Van der Geize R. *et al.* 2001. FEMS Microbiol. Lett. 205:197-202). Genuine *kstR* gene deletion was confirmed by the polymerase chain reaction (PCR) using forward primer (REG-FOR) 5'GGCGACGTTGCCGAGAATT 3' and reverse primer (REG-REV) 5'TCAGTGTCTGTGAGAGATTCA 3'. A PCR

10 amplicon of 618 bp was obtained with parent strain SQ1 genomic DNA (control). With genomic DNA of *kstR* gene deletion mutant strain RG10 the amplicon was reduced to 393 bp, confirming *kstR* gene deletion.

Constitutive *KstD1* expression was checked by growing cells of mutant strain RG10 and parent strain SQ1 in glucose (20 mM) mineral

15 medium (1 g·l⁻¹ NH₄NO₃, 0.25 g·l⁻¹ K₂HPO₄, 0.25 g·l⁻¹ MgSO₄·7H₂O, 5 mg·l⁻¹ NaCl, 5 mg·l⁻¹ FeSO₄·7H₂O (pH 7.2)) for 3 days at 30°C followed by steroid induction for 5 hours (0.5 g·l⁻¹ 4-androstene-3,17-dione (AD)). As a control, cell cultures without steroid induction were used. AD was solubilized in DMSO (50 mg·ml⁻¹) and added to the autoclaved medium. Cell pellets (30 min; 7,300 xg;

20 4°C) were washed with 200 ml phosphate buffer (KH₂PO₄ 2.72 g·l⁻¹; K₂HPO₄ 3.48 g·l⁻¹; MgSO₄·7H₂O 2.46 g·l⁻¹; pH 7.2). Washed cell suspensions (5 ml) were disrupted by double passage through a French pressure cell (140 Mpa). Cell extracts were centrifuged for 20 min at 25,000 xg to remove cell debris.

Expression of *kstD* was checked by native polyacrylamide gel electrophoresis

25 (PAGE) stained for KSTD activity (Van der Geize, R. *et al.* 2000. Appl. Environ. Microbiol. 66:2029-2036) (Table 1). A KSTD1 activity band was found with cell free extracts prepared from non-induced cells of strain RG10, indicating that *kstR* gene deletion results in constitutive expression of the *kstD* gene (Table 1).

Table 1. Constitutive *kstD* expression upon *kstR* unmarked gene deletion checked by native PAGE stained for KSTD1 activity.

steroid induction (AD or 9OHAD)	<i>kstD</i> expression	
	parent strain SQ1	<i>kstR</i> mutant strain RG10
-	-	+
+	+	+

Example 2. Constitutive expression of *KstD2* for microbial steroid Δ^1 -

5 dehydrogenation

A *kstR* gene deletion mutant strain of *R. erythropolis* RG9 (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018) was constructed, designated *R. erythropolis* RG17, using pREG104 (Fig.1, see example 1). Strain RG17 thus is a *kstD kstD2 kshA1 kstR* quadruple gene deletion mutant,
 10 lacking 3-ketosteroid Δ^1 -dehydrogenase (KSTD1 and KSTD2) and 3-ketosteroid 9 α -hydroxylase (KSH) activities, in addition to the transcription regulator of the *kstD* promoter. Due to the *kstD kstD2 kshA* phenotype of this mutant, strain RG17 is completely blocked in metabolizing 4-androstene-3,17-dione (AD), 1,4-androstadiene-3,17-dione (ADD) and 9 α -hydroxy-4-androstene-
 15 3,17-dione (9OHAD).

A *Rhodococcus* expression vector was constructed for the expression of genes under control of the *kstD* promoter of *R. erythropolis* SQ1 (Van der Geize, R. *et al.* 2000. Appl. Environ. Microbiol. 66:2029-2036). Using the *kstD* promoter, expression of genes in *R. erythropolis* mutant strains harboring a
 20 *kstR* gene deletion will be constitutive due to the absence of the repressor of *kstD* expression. The *kstD* promoter region (158 bp) was isolated from *R. erythropolis* SQ1 chromosomal DNA by PCR amplification (25 cycles: 30s 95°C, 30s 64°C, 30s 72°C, using *Taq* polymerase) using forward primer 5'ATAAAGCTTATCGATTATGTGTCCCGGCCGCGAAC3' and reverse primer
 25 5'ATAGGTACCATATGTGCGTCCTTACTCCAAGAGGG3'. A *NdeI* site (underlined) was incorporated in the amplicon to be able to clone genes of

interest precisely at the ATG startcodon of the *kstD* gene. The amplicon (175 bp) was blunt-ligated into the unique *Sna*BI restriction site of shuttle vector pRESQ (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018) and the resulting *Rhodococcus* expression vector was designated pRESX (Fig. 2).

5 The *kstD2* gene, encoding the KSTD2 isoenzyme in *R. erythropolis* SQ1, was isolated from chromosomal DNA of parent strain SQ1 by PCR (conditions: see above), using forward primer 5' GCGCATATGGCTAAGAATCAGGCACCC 3' (*Nde*I site underlined) and reverse primer 5' GCGGGATCCCTACTTCTCTGCTGCGTGATG 3' (*Bam*HI site underlined). The introduced *Nde*I and *Bam*HI sites were used to ligate the
10 *kstD2* amplicon into *Nde*I/*Bgl*III digested pRESX vector. The resulting plasmid was designated pRESX-KSTD2.

Plasmid pRESX-KSTD2 was introduced into *R. erythropolis* strain RG17 by electrotransformation (Van der Geize, R. *et al.* 2000. Appl. Environ.
15 Microbiol. 66:2029-2036) and one transformant was used for AD biotransformation. Biotransformation of AD into ADD by KSTD2 was performed with cultures grown in 100 ml YG15 (15 g·l⁻¹ yeast extract, 15 g·l⁻¹ glucose) medium at 28 °C (200 rpm) in the presence of kanamycine (200 µg·ml⁻¹). After growth till late exponential phase (OD₆₀₀ of 5 to 9), AD (1 g·l⁻¹ in 0.1%
20 [vol/vol] Tween80) was added and AD biotransformation into ADD was followed for several days. For HPLC analysis, culture samples were diluted 5 times with methanol/water (70:30) and filtered (0.45 µm). Steroids were analyzed by HPLC (with a 250- by 3-mm reversed phase Lichrosorb 10RP18 column [Varian Chrompack International, Middelburg, The Netherlands], UV
25 detection at 254 nm, and a liquid phase of methanol-water [60:40] at 35 °C).

Biotransformation experiments with cells of *R. erythropolis* strain RG17, harboring pRESX-KSTD2, showed the presence of KSTD2 steroid Δ¹-dehydrogenase activity resulting in biotransformation of AD into ADD to near completion. In contrast, *Rhodococcus* mutants with wild type KSTD1 and
30 KSTD2 isoenzymes, but blocked in the KSH reaction, convert AD into ADD in

yields usually not exceeding 50%, probably due to regulatory mechanisms (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018).

Example 3. Expression of *kshA* isogene *kshA2* complements the *kshA* mutant phenotype

A homologue of the *kshA* gene of *R. erythropolis* SQ1 (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018) was identified following nucleotide sequencing of DNA fragments isolated by complementation experiments of UV-induced *Rhodococcus* mutants. *R. erythropolis* SQ1 contains at least two *kshA* isogenes, which were designated *kshA* and *kshA2*.

R. erythropolis RG2, a *kshA* gene deletion mutant of *R. erythropolis* SQ1 (Van der Geize, R. *et al.* 2002. Mol. Microbiol. 45:1007-1018), does not show growth on mineral agar plates (1 g·l⁻¹ NH₄NO₃, 0.25 g·l⁻¹ K₂HPO₄, 0.25 g·l⁻¹ MgSO₄·7H₂O, 5 mg·l⁻¹ NaCl, 5 mg·l⁻¹ FeSO₄·7H₂O (pH 7.2), 1.5% agar) supplemented with AD (0.25 g·l⁻¹) as sole carbon and energy source. Thus, *kshA2* is not expressed under these growing conditions in *R. erythropolis* RG2.

The *kshA2* gene was placed under control of the *kstD* promoter in pRESX. In order to achieve this, the *kshA2* gene was amplified from *R. erythropolis* chromosomal DNA as template by PCR using forward primer 5'GGCCATATGTTGACACAGACGTGACGACC 3' (*Nde*I site underlined) and reverse primer 5' GCCACTAGTTCACTGCGCTGCTCCTGCACG 3' (*Spe*I site underlined). The obtained *kshA2* amplicon was first ligated into *Eco*RV digested pBlueScript (II)KS (pKSH311) and subsequently subcloned as a *Nde*I / *Spe*I fragment into *Nde*I / *Spe*I digested pRESX, resulting in pKSH312.

Plasmid pKSH312 was introduced into *R. erythropolis* RG2 by electrotransformation and the resulting transformants were replica plated onto mineral agar medium containing 0.25 g·l⁻¹ of AD as sole carbon and energy source. All transformants were able to grow on AD mineral medium, indicating functional expression of *kshA2* under control of the *kstD* promoter and complementation of the *kshA* mutant phenotype.

Example 4. Inducing steroids and constitutive expression.

In order to assess which steroids are able to induce the repressor-promoter system of the *KstD* gene, cell cultures of both *R. erythropolis* SQ1 (wildtype) and *R. erythropolis* RG10 (*kstR*-mutant) as described above were tested under inducing conditions with 1,4-androstadiene-3,17-dione (ADD), testosterone, progesterone, nardone, estron, 7 α -methyl-nardone, 11-methylene-nardone, stanolone (17 β OH-5 α -androstane-3-one), 19OH-7-dehydro-androstene-3,17-dione and pregnenolone were tested. 4-androstene-3,17-dione (AD) induction served as a positive control.

From induced cultures, cell free extracts were prepared as indicated above and tested for KSTD activity using DCPIP as an electron acceptor and AD as a substrate. With the exception of estron, it was found that all steroids tested were able to induce KSTD activity in *R. erythropolis* SQ1. The level of activity was not the same for all steroids tested. Controls on native gels confirmed that KSTD1 activity was indeed induced in all positive cases.

Further, it was investigated whether KSTD1 was constitutively expressed in *R. erythropolis* RG10. Cell free extracts were prepared from an AD-induced cell culture and from a non-induced cell culture. These extracts were tested for KSTD activity using DCPIP as an electron acceptor and AD as a substrate. For reasons of comparison, the same procedure was performed with *R. erythropolis* SQ1.

It was found that in both the induced as well as the non-induced culture of *R. erythropolis* RG10, KSTD activity was present. In *R. erythropolis* SQ1, on the other hand, KSTD activity was only detected in the AD-induced culture. Controls on native gels confirmed that KSTD1 activity was indeed induced in all positive cases.

Original (for SUBMISSION) - printed on Tuesday, 02 December, 2003 05:40:19 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	epoline® online filing PCT plug-in (updated 02.12.2003)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	2002.744_WO

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	13
1-2	line	12
1-3	Identification of Deposit	
1-3-1	Name of depositary Institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary Institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	09 October 2002 (09.10.2002)
1-3-4	Accession Number	DSMZ 15231
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	
0-4-1	Authorized officer	

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	

Claims

1. An isolated polynucleotide comprising a promoter from *Rhodococcus*, characterised in that said promoter is the *kstD* promoter.
2. Polynucleotide according to claim 1, wherein said *Rhodococcus* is *Rhodococcus erythropolis*.
- 5 3. Polynucleotide according to claim 1 or 2, characterised in that it comprises nucleotide 1-158 from the sequence of SEQ ID NO:3 or a functional part thereof.
4. Polynucleotide according to claims 1-3, further comprising a nucleotide sequence encoding a transcription regulator of said promoter.
- 10 5. Polynucleotide according to claim 4, wherein the expression of said nucleotide sequence is controlled by steroidal compounds.
6. Polynucleotide according to claim 5, wherein said regulator comprises the *kstR* gene or a homologue or a functional part thereof.
7. Polynucleotide according to any one of the preceding claims, further
15 comprising a nucleotide sequence encoding a polypeptide that is operably linked to said promoter.
8. Polynucleotide according to any one of the preceding claims, further comprising a selectable marker, a counter-selectable marker and/or a reporter gene.
- 20 9. Polynucleotide according to any one of the preceding claims, further comprising a signal sequence.
10. Recombinant vector comprising a polynucleotide according to any one of the claims 1-9.
11. Recombinant vector according to claim 10, further comprising
25 a nucleotide sequence having multiple cloning sites.
12. Host cell transformed with the recombinant vector according to claim 10 or 11.

13. Host cell according to claim 12, wherein said host cell is a bacterium from the order of Actinomycetales.
14. Bacterial host cell according to claim 13, wherein said host cell is selected from bacteria belonging to the families of *Actinomycetaceae*,
5 *Corynebacterineae*, *Mycobacteriaceae*, *Nocardiaceae*, *Brevibacteriaceae*, or *Micrococcaceae*.
15. Bacterial host cell according to claim 13, wherein said host cell is selected from bacteria belonging to the genus *Rhodococcus*.
16. Bacterial host cell according to claim 13, wherein said host cell is the
10 bacterium *Rhodococcus erythropolis* RG10 as deposited under number DSM 15231 with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen.
17. Host cell according to any one of claims 12-16, which does not contain a functional *kstR* gene or a homologue or a functional part thereof.
- 15 18. Method for producing a desired protein in a host cell, comprising transforming a host cell with a recombinant vector of claims 10 or 11.
19. A microbial expression system comprising a polynucleotide according to any one of the claims 1-9.
20. Method for constitutive expression of a protein of interest
20 comprising transforming a host cell according to claim 17 with a polynucleotide construct wherein the expression of the coding region of said protein is under control of the *kstD* promoter.
21. Use of a steroid for the induction of expression of a heterologous protein, which expression is under control of the *kstD* promoter, said steroid
25 lifting the repressor function exerted by the *kstR* gene product.
22. Method for identifying compounds that regulate the activity of the *kstD* promoter comprising exposing a host cell according to any one of the claims 12-17 to at least one compound whose ability to modulate the activity of a *kstD* promoter is to be determined, and monitoring said cell for modulated
30 *kstD* promoter activity.




Figure 1




Figure 2

SEQUENCE LISTING

<110> Akzo Nobel N.V.

<120> New expression system from Rhodococcus

<130>

<140>

<141>

<160> 13

<170> PatentIn-Ver. 2.1

<210> 1

<211> 1543

<212> DNA

<213> Rhodococcus erythropolis

<220>

<221> CDS

<222> (1)..(1533)

<400> 1

```

atg cag gac tgg acc agc gag tgc gac gtg ttg gta gtc ggc tcc ggc   48
Met Gln Asp Trp Thr Ser Glu Cys Asp Val Leu Val Val Gly Ser Gly
   1             5             10             15

ggc gga gcg ctg acc ggc gca tat acc gcc gct gct cag gga ttg acg   96
Gly Gly Ala Leu Thr Gly Ala Tyr Thr Ala Ala Ala Gln Gly Leu Thr
             20             25             30

acg atc gtc ctc gag aaa acc gat cgt ttc ggc ggg acc tcc gc c tac  144
Thr Ile Val Leu Glu Lys Thr Asp Arg Phe Gly Gly Thr Ser Ala Tyr
             35             40             45

tcg ggc gcc tcg atc tgg ctc cca ggt acc cag gtg cag gaa cgc gcc  192
Ser Gly Ala Ser Ile Trp Leu Pro Gly Thr Gln Val Gln Glu Arg Ala
             50             55             60

gga ctt ccc gac tcg acc gag aat gcc cgc acc tat ctg cgc gcg ttg  240
Gly Leu Pro Asp Ser Thr Glu Asn Ala Arg Thr Tyr Leu Arg Ala Leu
             65             70             75             80

ctc ggt gac gcc gag tcc gag cgc cag gac gcc tac gtc gag acc gct  288
Leu Gly Asp Ala Glu Ser Glu Arg Gln Asp Ala Tyr Val Glu Thr Ala
             85             90             95

ccc gct gtc gtc gct cta ctc gag cag aac ccg aac atc gaa ttc gag  336
Pro Ala Val Val Ala Leu Leu Glu Gln Asn Pro Asn Ile Glu Phe Glu
             100            105            110

ttc cgt gcg ttc ccc gac tac tac aaa gcc gaa ggc cgg atg gac acg  384
Phe Arg Ala Phe Pro Asp Tyr Tyr Lys Ala Glu Gly Arg Met Asp Thr
             115            120            125

gga cgc tcc atc aac cct ctc gat ctc gat ccc gcc gac atc ggt gac  432
Gly Arg Ser Ile Asn Pro Leu Asp Leu Asp Pro Ala Asp I le Gly Asp
             130            135            140

ctc gcc ggc aag gtg cgt ccg gaa ctg gac caa gac cgc acc ggt cag  480
Leu Ala Gly Lys Val Arg Pro Glu Leu Asp Gln Asp Arg Thr Gly Gln
             145            150            155            160

gat cat gct ccc ggc ccg atg atc ggt ggg cgc gca ctg atc ggc cgt  528
Asp His Ala Pro Gly Pro Met Ile Gly Gly Arg Ala Leu Ile Gly Arg
             165            170            175

```

ctg ctg gcc gca gtt cag agc acc ggt aag gca gaa ctt cgc acc gaa	576
Leu Leu Ala Ala Val Gln Ser Thr Gly Lys Ala Glu Leu Arg Thr Glu	
180 185 190	
tcc gtc ctc acc tcc ctg atc gtg gaa gac ggc cgt gtt gtc ggc gcc	624
Ser Val Leu Thr Ser Leu Ile Val Glu Asp Gly Arg Val Val Gly Ala	
195 200 205	
gag gtc gaa tcc ggc ggc gaa acc cag cga atc aag gcg aac cgc ggt	672
Glu Val Glu Ser Gly Gly Glu Thr Gln Arg Ile Lys Ala Asn Arg Gly	
210 215 220	
gtc ctg atg gca gca ggc ggc atc gaa ggc aac gcc gag atg cgt gag	720
Val Leu Met Ala Ala Gly Gly Ile Glu Gly Asn Ala Glu Met Arg Glu	
225 230 235 240	
cag gca ggc acc ccc ggc aag gcg atc tgg agt atg ggt ccc ttc ggc	768
Gln Ala Gly Thr Pro Gly Lys Ala Ile Trp Ser Met Gly Pro Phe Gly	
245 250 255	
gcc aac acc ggc gac gcg atc tct gcc ggt att gc t gtc ggc ggc gca	816
Ala Asn Thr Gly Asp Ala Ile Ser Ala Gly Ile Ala Val Gly Gly Ala	
260 265 270	
aca gcc ttg ctc gat cag gcg tgg ttc tgc ccc ggc gtc gag cag ccc	864
Thr Ala Leu Leu Asp Gln Ala Trp Phe Cys Pro Gly Val Glu Gln Pro	
275 280 285	
gac ggc agc gcc gcc ttc atg gtc ggc gtt cgc ggt ggc ctc gtc gtc	912
Asp Gly Ser Ala Ala Phe Met Val Gly Val Arg Gly Gly Leu Val Val	
290 295 300	
gac agc gcc ggt gag cgc tac ctc aac gag tgc ctt ccg tac gac cag	960
Asp Ser Ala Gly Glu Arg Tyr Leu Asn Glu Ser Leu Pro Tyr Asp Gln	
305 310 315 320	
ttc gga cga gcc atg gat gct cac gac gac aac ggt tct gcc gtg ccg	1008
Phe Gly Arg Ala Met Asp Ala His Asp Asn Gly Ser Ala Val Pro	
325 330 335	
tcg ttc atg atc ttc gac tcg cgc gag ggt ggc gga ctg ccc gcc atc	1056
Ser Phe Met Ile Phe Asp Ser Arg Glu Gly Gly Gly Leu Pro Ala Ile	
340 345 350	
tgc atc ccg aac acg gcg ccc gcc aag cac ctc gaa gcc gga acg tgg	1104
Cys Ile Pro Asn Thr Ala Pro Ala Lys His L eu Glu Ala Gly Thr Trp	
355 360 365	
gtc ggt gcc gac act ctc gaa gaa ctc gct gcc aag acc gga cta ccg	1152
Val Gly Ala Asp Thr Leu Glu Glu Leu Ala Ala Lys Thr Gly Leu Pro	
370 375 380	
gcc gac gca ttg cgc agc act gtc gaa aag ttc aac gat gcc gca aaa	1200
Ala Asp Ala Leu Arg Ser Thr Val Glu Lys Phe Asn Asp Ala Ala Lys	
385 390 395 400	
ctg ggc gtc gac gaa gag ttc cat cgc ggc gaa gac ccg tac gac gcg	1248
Leu Gly Val Asp Glu Glu Phe His Arg Gly Glu Asp Pro Tyr Asp Ala	
405 410 415	
ttc ttc tgc cca ccc aac ggc ggt gcg aat gcg gca ctg acg gcc atc	1296
Phe Phe Cys Pro Pro Asn Gly Gly Ala Asn Ala Ala Leu Thr Ala Ile	
420 425 430	
gag aac gga ccg ttc tac gcg gcc cgc atc gtc ctc agt gac ctc ggc	1344
Glu Asn Gly Pro Phe Tyr Ala Ala Arg Ile Val Leu Ser Asp Leu Gly	

```

      435              440              445
acc aag ggc gga ttg gtc acc gac gtc aac ggc cga gtc ctg cgt gct 1392
Thr Lys Gly Gly Leu Val Thr Asp Val Asn Gly Arg Val Leu Arg Ala
      450              455              460

gac ggc agc gcc atc gac ggc ctg tac gcc gcc ggc aac acg agc gcg 1440
Asp Gly Ser Ala Ile Asp Gly Leu Tyr Ala Ala Gly Asn Thr Ser Ala
465              470              475              480

tca ctg agc ggc cgc ttc tac ccc ggc ccc gga gtt cca ctc ggc acg 1488
Ser Leu Ser Gly Arg Phe Tyr Pro Gly Pro Gly Val Pro Leu Gly Thr
      485              490              495

gct atg gtc ttc tcg tac cga gca gct cag gac atg gcg aag taa 1533
Ala Met Val Phe Ser Tyr Arg Ala Ala Gln Asp Met Ala Lys
      500              505              510

cgcagttcaa 1543

```

```

<210> 2
<211> 511
<212> PRT
<213> Rhodococcus erythropolis

```

```

<400> 2
Met Gln Asp Trp Thr Ser Glu Cys Asp Val Leu Val Val Gly Ser Gly
 1              5              10              15

Gly Gly Ala Leu Thr Gly Ala Tyr Thr Ala Ala Ala Gln Gly Leu Thr
      20              25              30

Thr Ile Val Leu Glu Lys Thr Asp Arg Phe Gly Gly Thr Ser Ala Tyr
      35              40              45

Ser Gly Ala Ser Ile Trp Leu Pro Gly Thr Gln Val Gln Glu Arg Ala
      50              55              60

Gly Leu Pro Asp Ser Thr Glu Asn Ala Arg Thr Tyr Leu Arg Ala Leu
      65              70              75              80

Leu Gly Asp Ala Glu Ser Glu Arg Gln Asp Ala Tyr Val Glu Thr Ala
      85              90              95

Pro Ala Val Val Ala Leu Leu Glu Gln Asn Pro Asn Ile Glu Phe Glu
      100             105             110

Phe Arg Ala Phe Pro Asp Tyr Tyr Lys Ala Glu Gly Arg Met Asp Thr
      115             120             125

Gly Arg Ser Ile Asn Pro Leu Asp Leu Asp Pro Ala Asp Ile Gly Asp
      130             135             140

Leu Ala Gly Lys Val Arg Pro Glu Leu Asp Gln Asp Arg Thr Gly Gln
      145             150             155             160

Asp His Ala Pro Gly Pro Met Ile Gly Gly Arg Ala Leu Ile Gly Arg
      165             170             175

Leu Leu Ala Ala Val Gln Ser Thr Gly Lys Ala Glu Leu Arg Thr Glu
      180             185             190

Ser Val Leu Thr Ser Leu Ile Val Glu Asp Gly Arg Val Val Gly Ala
      195             200             205

Glu Val Glu Ser Gly Gly Glu Thr Gln Arg Ile Lys Ala Asn Arg Gly

```

210 215 220
 Val Leu Met Ala Ala Gly Gly Ile Glu Gly Asn Ala Glu Met Arg Glu
 225 230 235 240
 Gln Ala Gly Thr Pro Gly Lys Ala Ile Trp Ser Met Gly Pro Phe Gly
 245 250 255
 Ala Asn Thr Gly Asp Ala Ile Ser Ala Gly Ile Ala Val Gly Gly Ala
 260 265 270
 Thr Ala Leu Leu Asp Gln Ala Trp Phe Cys Pro Gly Val Glu Gln Pro
 275 280 285
 Asp Gly Ser Ala Ala Phe Met Val Gly Val Arg Gly Gly Leu Val Val
 290 295 300
 Asp Ser Ala Gly Glu Arg Tyr Leu Asn Glu Ser Leu Pro Tyr Asp Gln
 305 310 315 320
 Phe Gly Arg Ala Met Asp Ala His Asp Asp Asn Gly Ser Ala Val Pro
 325 330 335
 Ser Phe Met Ile Phe Asp Ser Arg Glu Gly Gly Gly Leu Pro Ala Ile
 340 345 350
 Cys Ile Pro Asn Thr Ala Pro Ala Lys His Leu Glu Ala Gly Thr Trp
 355 360 365
 Val Gly Ala Asp Thr Leu Glu Glu Leu Ala Ala Lys Thr Gly Leu Pro
 370 375 380
 Ala Asp Ala Leu Arg Ser Thr Val Glu Lys Phe Asn Asp Ala Ala Lys
 385 390 395 400
 Leu Gly Val Asp Glu Glu Phe His Arg Gly Glu Asp Pro Tyr Asp Ala
 405 410 415
 Phe Phe Cys Pro Pro Asn Gly Gly Ala Asn Ala Ala Leu Thr Ala Ile
 420 425 430
 Glu Asn Gly Pro Phe Tyr Ala Ala Arg Ile Val Leu Ser Asp Leu Gly
 435 440 445
 Thr Lys Gly Gly Leu Val Thr Asp Val Asn Gly Arg Val Leu Arg Ala
 450 455 460
 Asp Gly Ser Ala Ile Asp Gly Leu Tyr Ala Ala Gly Asn Thr Ser Ala
 465 470 475 480
 Ser Leu Ser Gly Arg Phe Tyr Pro Gly Pro Gly Val Pro Leu Gly Thr
 485 490 495
 Ala Met Val Phe Ser Tyr Arg Ala Ala Gln Asp Met Ala Lys
 500 505 510

<210> 3

<211> 158

<212> DNA

<213> Rhodococcus erythropolis

<400> 3

atcatcgatt atgtgtcccg gccggaacg a ccgcgctaa ttctctcacc tggaccaccc 60

atctcggcat attgcccgct cagtgggacc tggcatggcc ttccagtgcc gtgcggtatt 120

ccgtggacac cccaccctct tggagtaagg acgcaatg 158

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 4
ggcgacgttg ccgagaatt 19

<210> 5
<211> 624
<212> DNA
<213> Rhodococcus erythropolis

<220>
<221> CDS
<222> (1)..(624)

<400> 5
atg ggg gcg acg ttg ccg aga att gcc gag gtc agg gac gct gct gag 48
Met Gly Ala Thr Leu Pro Arg Ile Ala Glu Val Arg Asp Ala Ala Glu
1 5 10 15
ccc agt tcg gac gag cag cgg gcg cgc cat gtg cgg atg ctg gaa gcg 96
Pro Ser Ser Asp Glu Gln Arg Ala Arg His Val Arg Met Leu Glu Ala
20 25 30
gcc gcc gaa ttg ggg acc gag aaa gaa ctc tca cgg gtt cag atg cac 144
Ala Ala Glu Leu Gly Thr Glu Lys Glu Leu Ser Arg Val Gln Met Hi s
35 40 45
gaa gtt gcc aag cgg gca ggc gtg gcc atc ggc act ctc tac cgc tat 192
Glu Val Ala Lys Arg Ala Gly Val Ala Ile Gly Thr Leu Tyr Arg Tyr
50 55 60
ttc cct tcg aag acg cac ctc ttc gtc gct gtg atg gtc gag cag atc 240
Phe Pro Ser Lys Thr His Leu Phe Val Ala Val Met Val Glu Gln Ile
65 70 75 80
gat cag atc ggc gac agt ttc gcc aag cat c ag gtg cag tcg gcc aat 288
Asp Gln Ile Gly Asp Ser Phe Ala Lys His Gln Val Gln Ser Ala Asn
85 90 95
ccg cag gac gcc gtg tac gag gtc ctg gtg cgc gcg act cgc ggg tta 336
Pro Gln Asp Ala Val Tyr Glu Val Leu Val Arg Ala Thr Arg Gly Leu
100 105 110
ctg cgt cgg ccg gcc ctt tcg act gcg atg ctg cag tcg tcc agt acc 384
Leu Arg Arg Pro Ala Leu Ser Thr Ala Met Leu Gln Ser Ser Ser Thr
115 120 125
gcc aac gtc gcg acg gtg ccg gac gtg ggc aag atc gat cgc gcc ttc 432
Ala Asn Val Ala Thr Val Pro Asp Val Gly Lys Ile Asp Arg Gly Phe
130 135 140
cgg cag atc atc ctc gat gcg gcc ggg atc gag aac ccg acc gag gaa 480
Arg Gln Ile Ile Leu Asp Ala Ala Gly Ile Glu Asn Pro Thr Glu Glu
145 150 155 160
gac aac acc ggg ttg cgt ctg ctg atg cag ctg tgg ttc ggg gtc atc 528
Asp Asn Thr Gly Leu Arg Leu Leu Met Gln Leu Trp Phe Gly Val Ile


```

          165              170              175
caa tcg tgc ctc aac ggt cga att tcc atc ccg gat gcg gag tac gac 576
Gln Ser Cys Leu Asn Gly Arg Ile Ser Ile Pro Asp Ala Glu Tyr Asp
          180              185              190

atc cgc aag ggg tgc gac ctg ctt ctg gtg aat ctc tca cga cac tga 624
Ile Arg Lys Gly Cys Asp Leu Leu Leu Val Asn Leu Ser Arg His
          195              200              205

```

<210> 6
 <211> 208
 <212> PRT
 <213> Rhodococcus erythropolis

```

<400> 6
Met Gly Ala Thr Leu Pro Arg Ile Ala Glu Val Arg Asp Ala Ala Glu
  1              5              10              15

Pro Ser Ser Asp Glu Gln Arg Ala Arg His Val Arg Met Leu Glu Ala
          20              25              30

Ala Ala Glu Leu Gly Thr Glu Lys Glu Leu Ser Arg Val Gln Met His
          35              40              45

Glu Val Ala Lys Arg Ala Gly Val Ala Ile Gly Thr Leu Tyr Arg Tyr
          50              55              60

Phe Pro Ser Lys Thr His Leu Phe Val Ala Val Met Val Glu Gln Ile
          65              70              75              8 0

Asp Gln Ile Gly Asp Ser Phe Ala Lys His Gln Val Gln Ser Ala Asn
          85              90              95

Pro Gln Asp Ala Val Tyr Glu Val Leu Val Arg Ala Thr Arg Gly Leu
          100             105             110

Leu Arg Arg Pro Ala Leu Ser Thr Ala Met Leu Gln Ser Ser Ser Thr
          115             120             125

Ala Asn Val Ala Thr Val Pro Asp Val Gly Lys Ile Asp Arg Gly Phe
          130             135             140

Arg Gln Ile Ile Leu Asp Ala Ala Gly Ile Glu Asn Pro Thr Glu Glu
          145             150             155             160

Asp Asn Thr Gly Leu Arg Leu Leu Met Gln Leu Trp Phe Gly Val Ile
          165             170             175

Gln Ser Cys Leu Asn Gly Arg Ile Ser Ile Pro Asp Ala Glu Tyr Asp
          180             185             190

Ile Arg Lys Gly Cys Asp Leu Leu Leu Val Asn Leu Ser Arg His
          195             200             205

```

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 7
 tcagtgtcgt gagagattca

<210> 8
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 8
ataaaagctta tcgattatgt gtcccgccg cgaac 35

<210> 9
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 9
ataggtacca tatgtgcgtc cttactcaa gaggg 35

<210> 10
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 10
gcgcataatgg ctaagaatca ggcaccc 27

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 11
gcgggatccc tactttctctg ctgcgtgatg 30

<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 12
ggccatatgt tgaccacaga cgtgacgacc 30

<210> 13
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 13

gccactagtt cactgcgctg ctctgcacg

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50928

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/76 C12N15/11 C12N1/21 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, EMBASE, BIOSIS, EMBL, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VAN DER GEIZE R ET AL: "Targeted Disruption of the kstD Gene Encoding a 3-Ketosteroid delta1-Dehydrogenase Isoenzyme of Rhodococcus erythropolis Strain SQ1"</p> <p>APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 66, no. 5, May 2000 (2000-05), pages 2029-2036, XP002157019</p> <p>ISSN: 0099-2240</p> <p>cited in the application</p> <p>page 2031, left-hand column, paragraph 2</p> <p>-page 2031, right-hand column, paragraph 1; figure 3</p> <p>page 2035, left-hand column, paragraph 2</p> <p>-& DATABASE EMBL 'Online!'</p> <p>DNA, 2398 bp,</p> <p>23 December 1999 (1999-12-23)</p> <p>VAN DER GEIZE R. ET AL: "Rhodococcus</p> <p style="text-align: center;">-/--</p>	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

26 May 2004

Date of mailing of the international search report

04/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bladier, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/50928

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>erythropolis hypothetical repressor protein KstR (kstR) and 3-ketosteroid dehydrogenase (kstD1) genes, complete cds." retrieved from EBI Database accession no. AF096929 XP002232947 the whole document</p> <p style="text-align: center;">---</p>	
X	<p>WO 01/31050 A (AKZO NOBEL NV; HESSELS GERDA (NL); DIJKHUIZEN LUBBERT (NL); GEIZE) 3 May 2001 (2001-05-03) cited in the application * SEQ ID N 1 * claim 14; example 1</p> <p style="text-align: center;">---</p>	1-22
A	<p>MOLNAR I ET AL: "Molecular cloning, expression in Streptomyces lividans, and analysis of a gene cluster from Arthrobacter simplex encoding 3-ketosteroid-delta1-dehydrogenase, 3-ketosteroid-delta 5-isomerase and a hypothetical regulatory protein" MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 15, no. 5, March 1995 (1995-03), pages 895-905, XP000926143 ISSN: 0950-382X cited in the application page 901, left-hand column, line 8 - line 30; figure 2</p> <p style="text-align: center;">---</p>	
A	<p>KAUFMANN G ET AL.: "Steroid-1-dehydrogenase of Rhodococcus erythropolis: purification and N-terminal amino acid sequence." J STEROID BIOCHEM MOL BIOL, vol. 43, no. 4, 1992, pages 297-301, XP009006809</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50928

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0131050	A	03-05-2001	AU 1514501 A	08-05-2001
			CA 2396879 A1	03-05-2001
			CN 1413260 T	23-04-2003
			CZ 20021784 A3	14-08-2002
			WO 0131050 A1	03-05-2001
			EP 1232278 A1	21-08-2002
			NO 20022449 A	19-06-2002
			ZA 200203915 A	18-08-2003
<hr/>				